Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
Colin Sauder, Luke A. Allen, Elizabeth Baker, Andrew C. Miller, Steven M. Paul, Stephen K. Brannan
Dive into the research topics of 'Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study'. Together they form a unique fingerprint.